Literature DB >> 3322851

Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2.

S M Scotland1, G A Willshaw, H R Smith, B Rowe.   

Abstract

Fifty-four strains of Escherichia coli belonging to serogroup O157 were examined for the production of Vero cytotoxins VT1 and VT2, and for other properties such as plasmid content, resistance to antimicrobial agents and colicin production. Twenty-six strains from cases of diarrhoea, haemorrhagic colitis and haemolytic uraemic syndrome in humans produced VT. By serum neutralization tests and hybridization with DNA probes for VT1 or VT2, three classes were recognized which produced either VT1 alone or VT2 alone or both VT1 and VT2. These strains were of H type 7 or non-motile. The strains producing VT were sensitive to all the antimicrobial agents tested, and all carried at least one plasmid which had a molecular weight of c. 60 X 10(6). Seven strains of porcine origin and 21 strains of human origin did not produce VT or hybridize with either DNA probe. None of these strains was of H type 7. Of the 21 human VT- strains, 17 were of extra-intestinal origin and 18 were of H type 45. Twenty-three of the 28 VT-strains were resistant to at least one antimicrobial agent.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3322851      PMCID: PMC2249237          DOI: 10.1017/s0950268800066462

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  35 in total

1.  A rapid alkaline extraction procedure for screening recombinant plasmid DNA.

Authors:  H C Birnboim; J Doly
Journal:  Nucleic Acids Res       Date:  1979-11-24       Impact factor: 16.971

2.  Cytotoxic Escherichia coli O157:H7 associated with haemorrhagic colitis in Canada.

Authors:  W M Johnson; H Lior; G S Bezanson
Journal:  Lancet       Date:  1983-01-01       Impact factor: 79.321

3.  Isolation of Escherichia coli O157:H7 from dairy cattle associated with two cases of haemolytic uraemic syndrome.

Authors:  M L Martin; L D Shipman; J G Wells; M E Potter; K Hedberg; I K Wachsmuth; R V Tauxe; J P Davis; J Arnoldi; J Tilleli
Journal:  Lancet       Date:  1986-11-01       Impact factor: 79.321

4.  Bovine reservoir for verotoxin-producing Escherichia coli O157:H7.

Authors:  A A Borczyk; M A Karmali; H Lior; L M Duncan
Journal:  Lancet       Date:  1987-01-10       Impact factor: 79.321

5.  Two new Escherichia coli O antigens, O150 and O157, and one new K antigen, K92, in strains isolated from veterinary diseases.

Authors:  A J Furowicz; F Orskov
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1972

6.  Test for Escherichia coli enterotoxin using infant mice: application in a study of diarrhea in children in Honolulu.

Authors:  A G Dean; Y C Ching; R G Williams; L B Harden
Journal:  J Infect Dis       Date:  1972-04       Impact factor: 5.226

7.  Heterogeneity of Escherichia coli phages encoding Vero cytotoxins: comparison of cloned sequences determining VT1 and VT2 and development of specific gene probes.

Authors:  G A Willshaw; H R Smith; S M Scotland; A M Field; B Rowe
Journal:  J Gen Microbiol       Date:  1987-05

8.  Haemorrhagic colitis and Vero-cytotoxin-producing Escherichia coli in England and Wales.

Authors:  H R Smith; B Rowe; R J Gross; N K Fry; S M Scotland
Journal:  Lancet       Date:  1987-05-09       Impact factor: 79.321

9.  Vero response to a cytotoxin of Escherichia coli.

Authors:  J Konowalchuk; J I Speirs; S Stavric
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

10.  Application of agarose gel electrophoresis to the characterization of plasmid DNA in drug-resistant enterobacteria.

Authors:  G A Willshaw; H R Smith; E S Anderson
Journal:  J Gen Microbiol       Date:  1979-09
View more
  62 in total

1.  Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells.

Authors:  B P Hurley; M Jacewicz; C M Thorpe; L L Lincicome; A J King; G T Keusch; D W Acheson
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  Effects of Shiga toxin 2 on lethality, fetuses, delivery, and puerperal behavior in pregnant mice.

Authors:  K Yoshimura; J Fujii; A Tanimoto; T Yutsudo; M Kashimura; S Yoshida
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

3.  Toxicity of Shiga toxin 1 in the central nervous system of rabbits.

Authors:  J Fujii; Y Kinoshita; T Yutsudo; H Taniguchi; T Obrig; S I Yoshida
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

4.  Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood.

Authors:  P C Rowe
Journal:  Can J Infect Dis       Date:  1995-03

Review 5.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 6.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

7.  Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice.

Authors:  J Fujii; T Kita; S Yoshida; T Takeda; H Kobayashi; N Tanaka; K Ohsato; Y Mizuguchi
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans.

Authors:  P Boerlin; S A McEwen; F Boerlin-Petzold; J B Wilson; R P Johnson; C L Gyles
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

9.  Characterization of verocytotoxin-producing Escherichia coli O157 isolates from patients with haemolytic uraemic syndrome in Western Europe.

Authors:  A E Heuvelink; N C van de Kar; J F Meis; L A Monnens; W J Melchers
Journal:  Epidemiol Infect       Date:  1995-08       Impact factor: 2.451

10.  Expression and purification of Shiga-like toxin II B subunits.

Authors:  D W Acheson; S A De Breucker; M Jacewicz; L L Lincicome; A Donohue-Rolfe; A V Kane; G T Keusch
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.